Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129


An update on pathogenesis and diagnosis of thrombotic thrombocytopenic purpura.

Joly BS, Coppo P, Veyradier A.

Expert Rev Hematol. 2019 Jun;12(6):383-395. doi: 10.1080/17474086.2019.1611423. Epub 2019 May 20.


Inherited Thrombotic Thrombocytopenic Purpura Revealed by Recurrent Strokes in a Male Adult: Case Report and Literature Review.

Beauvais D, Venditti L, Chassin O, Joly B, Ameri A, Boisseau P, Lambotte O, Coppo P, Veyradier A, Denier C.

J Stroke Cerebrovasc Dis. 2019 Jun;28(6):1537-1539. doi: 10.1016/j.jstrokecerebrovasdis.2019.03.011. Epub 2019 Mar 28. Review.


[Von Willebrand disease in the elderly].

Itzhar-Baïkian N, Veyradier A, Dillinger JG, Stepanian A, Pautas É, Siguret V.

Rev Prat. 2018 Dec;68(10):1125-1131. French.


Transfer of ADAMTS13 antibody-mediated thrombotic thrombocytopenic purpura via kidney transplantation.

Zafrani L, Dekimpe C, Joly BS, Roose E, Fieux F, Azoulay E, Peraldi MN, Durrbach A, Coppo P, Vanhoorelbeke K, Veyradier A.

Haematologica. 2019 Jun;104(6):e277-e280. doi: 10.3324/haematol.2019.219063. Epub 2019 Feb 28. No abstract available.


Generation of anti-idiotypic antibodies to detect anti-spacer antibody idiotopes in acute thrombotic thrombocytopenic purpura patients.

Schelpe AS, Roose E, Joly BS, Pareyn I, Mancini I, Biganzoli M, Deckmyn H, Voorberg J, Fijnheer R, Peyvandi F, De Meyer SF, Coppo P, Veyradier A, Vanhoorelbeke K.

Haematologica. 2019 Jun;104(6):1268-1276. doi: 10.3324/haematol.2018.205666. Epub 2018 Dec 6.


ADAMTS13 Gene Mutations Influence ADAMTS13 Conformation and Disease Age-Onset in the French Cohort of Upshaw-Schulman Syndrome.

Joly BS, Boisseau P, Roose E, Stepanian A, Biebuyck N, Hogan J, Provot F, Delmas Y, Garrec C, Vanhoorelbeke K, Coppo P, Veyradier A; French Reference Center for Thrombotic Microangiopathies.

Thromb Haemost. 2018 Nov;118(11):1902-1917. doi: 10.1055/s-0038-1673686. Epub 2018 Oct 12.


Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura.

Jestin M, Benhamou Y, Schelpe AS, Roose E, Provôt F, Galicier L, Hié M, Presne C, Poullin P, Wynckel A, Saheb S, Deligny C, Servais A, Girault S, Delmas Y, Kanouni T, Lautrette A, Chauveau D, Mousson C, Perez P, Halimi JM, Charvet-Rumpler A, Hamidou M, Cathébras P, Vanhoorelbeke K, Veyradier A, Coppo P; French Thrombotic Microangiopathies Reference Center.

Blood. 2018 Nov 15;132(20):2143-2153. doi: 10.1182/blood-2018-04-840090. Epub 2018 Sep 10.


Early Differentiation of Shiga Toxin-Associated Hemolytic Uremic Syndrome in Critically Ill Adults With Thrombotic Microangiopathy Syndromes.

Joseph A, Rafat C, Zafrani L, Mariani-Kurkdjian P, Veyradier A, Hertig A, Rondeau E, Mariotte E, Azoulay E.

Crit Care Med. 2018 Sep;46(9):e904-e911. doi: 10.1097/CCM.0000000000003292.


Pediatric thrombotic thrombocytopenic purpura.

Joly BS, Coppo P, Veyradier A.

Eur J Haematol. 2018 Oct;101(4):425-434. doi: 10.1111/ejh.13107. Epub 2018 Aug 22. Review.


The clinical features of cardiac involvement in patients with severe thrombotic thrombocytopenic purpura.

Fourmont AM, Zafrani L, Mariotte E, Galicier L, Joly B, Merceron S, Bertinchamp R, Lemiale V, de Jong A, Valade S, Darmon M, Veyradier A, Azoulay E.

Intensive Care Med. 2018 Jun;44(6):963-965. doi: 10.1007/s00134-018-5216-7. Epub 2018 May 11. No abstract available.


Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay between genes and environmental triggers.

Hrdinová J, D'Angelo S, Graça NAG, Ercig B, Vanhoorelbeke K, Veyradier A, Voorberg J, Coppo P.

Haematologica. 2018 Jul;103(7):1099-1109. doi: 10.3324/haematol.2016.151407. Epub 2018 Apr 19. Review.


Deep venous thrombosis treated by rivaroxaban in a young patient with type Ia carbohydrate-deficient glycoprotein (CDG) syndrome.

Lefrère B, Stepanian A, Itzhar-Baïkian N, Charles P, Hadj-Ali A, Joly B, Alhenc-Gelas M, Drouet L, Veyradier A, Siguret V.

Ann Biol Clin (Paris). 2018 Apr 1;76(2):217-223. doi: 10.1684/abc.2018.1324.


Understanding thrombotic microangiopathies in children.

Joly BS, Zheng XL, Veyradier A.

Intensive Care Med. 2018 Sep;44(9):1536-1538. doi: 10.1007/s00134-018-5059-2. Epub 2018 Jan 24. No abstract available.


An open conformation of ADAMTS-13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura.

Roose E, Schelpe AS, Joly BS, Peetermans M, Verhamme P, Voorberg J, Greinacher A, Deckmyn H, De Meyer SF, Coppo P, Veyradier A, Vanhoorelbeke K.

J Thromb Haemost. 2018 Feb;16(2):378-388. doi: 10.1111/jth.13922. Epub 2018 Jan 23.


Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in mice.

Tersteeg C, Joly BS, Gils A, Lijnen R, Deckmyn H, Declerck PJ, Plaimauer B, Coppo P, Veyradier A, Maas C, De Meyer SF, Vanhoorelbeke K.

J Thromb Haemost. 2017 Dec;15(12):2432-2442. doi: 10.1111/jth.13859. Epub 2017 Oct 27.


The ADAMTS131239-1253 peptide is a dominant HLA-DR1-restricted CD4+ T-cell epitope.

Gilardin L, Delignat S, Peyron I, Ing M, Lone YC, Gangadharan B, Michard B, Kherabi Y, Sharma M, Pashov A, Latouche JB, Hamieh M, Toutirais O, Loiseau P, Galicier L, Veyradier A, Kaveri S, Maillère B, Coppo P, Lacroix-Desmazes S.

Haematologica. 2017 Nov;102(11):1833-1841. doi: 10.3324/haematol.2015.136671. Epub 2017 Jul 27.


Predictive features of chronic kidney disease in atypical haemolytic uremic syndrome.

Jamme M, Raimbourg Q, Chauveau D, Seguin A, Presne C, Perez P, Gobert P, Wynckel A, Provôt F, Delmas Y, Mousson C, Servais A, Vrigneaud L, Veyradier A, Rondeau E, Coppo P; French Thrombotic Microangiopathies Reference Centre.

PLoS One. 2017 May 18;12(5):e0177894. doi: 10.1371/journal.pone.0177894. eCollection 2017.


Thrombotic thrombocytopenic purpura.

Joly BS, Coppo P, Veyradier A.

Blood. 2017 May 25;129(21):2836-2846. doi: 10.1182/blood-2016-10-709857. Epub 2017 Apr 17. Review.


Thrombotic thrombocytopenic purpura misdiagnosed as autoimmune cytopenia: Causes of diagnostic errors and consequence on outcome. Experience of the French thrombotic microangiopathies reference centre.

Grall M, Azoulay E, Galicier L, Provôt F, Wynckel A, Poullin P, Grange S, Halimi JM, Lautrette A, Delmas Y, Presne C, Hamidou M, Girault S, Pène F, Perez P, Kanouni T, Seguin A, Mousson C, Chauveau D, Ojeda-Uribe M, Barbay V, Veyradier A, Coppo P, Benhamou Y.

Am J Hematol. 2017 Apr;92(4):381-387. doi: 10.1002/ajh.24665. Epub 2017 Feb 21.


Understanding therapeutic targets in thrombotic thrombocytopenic purpura.

Joly BS, Vanhoorelbeke K, Veyradier A.

Intensive Care Med. 2017 Sep;43(9):1398-1400. doi: 10.1007/s00134-016-4662-3. Epub 2017 Jan 23. No abstract available.


Assessment of endothelial damage and cardiac injury in a mouse model mimicking thrombotic thrombocytopenic purpura.

Le Besnerais M, Favre J, Denis CV, Mulder P, Martinet J, Nicol L, Levesque H, Veyradier A, Kopić A, Motto DG, Coppo P, Richard V, Benhamou Y.

J Thromb Haemost. 2016 Oct;14(10):1917-1930. doi: 10.1111/jth.13439. Epub 2016 Sep 28.


Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy.

Joly BS, Stepanian A, Leblanc T, Hajage D, Chambost H, Harambat J, Fouyssac F, Guigonis V, Leverger G, Ulinski T, Kwon T, Loirat C, Coppo P, Veyradier A; French Reference Center for Thrombotic Microangiopathies.

Lancet Haematol. 2016 Nov;3(11):e537-e546. doi: 10.1016/S2352-3026(16)30125-9. Epub 2016 Oct 3.


Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: Results of a phase II, multicenter noncomparative study.

Benhamou Y, Paintaud G, Azoulay E, Poullin P, Galicier L, Desvignes C, Baudel JL, Peltier J, Mira JP, Pène F, Presne C, Saheb S, Deligny C, Rousseau A, Féger F, Veyradier A, Coppo P; French Reference Center for Thrombotic Microangiopathies.

Am J Hematol. 2016 Dec;91(12):1246-1251. doi: 10.1002/ajh.24559. Epub 2016 Nov 8.


Thrombotic Thrombocytopenic Purpura in Black People: Impact of Ethnicity on Survival and Genetic Risk Factors.

Martino S, Jamme M, Deligny C, Busson M, Loiseau P, Azoulay E, Galicier L, Pène F, Provôt F, Dossier A, Saheb S, Veyradier A, Coppo P; French Reference Center for Thrombotic Microangiopathies.

PLoS One. 2016 Jul 6;11(7):e0156679. doi: 10.1371/journal.pone.0156679. eCollection 2016.


Autoimmune thrombotic thrombocytopenic purpura associated with HHV8-related Multicentric Castleman disease.

London J, Boutboul D, Agbalika F, Coppo P, Veyradier A, Gérard L, Oksenhendler E, Azoulay E, Galicier L.

Br J Haematol. 2017 Aug;178(3):486-488. doi: 10.1111/bjh.14152. Epub 2016 May 25. No abstract available.


Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy.

Mariotte E, Azoulay E, Galicier L, Rondeau E, Zouiti F, Boisseau P, Poullin P, de Maistre E, Provôt F, Delmas Y, Perez P, Benhamou Y, Stepanian A, Coppo P, Veyradier A; French Reference Center for Thrombotic Microangiopathies.

Lancet Haematol. 2016 May;3(5):e237-45. doi: 10.1016/S2352-3026(16)30018-7. Epub 2016 Apr 16.


A Laboratory Phenotype/Genotype Correlation of 1167 French Patients From 670 Families With von Willebrand Disease: A New Epidemiologic Picture.

Veyradier A, Boisseau P, Fressinaud E, Caron C, Ternisien C, Giraud M, Zawadzki C, Trossaert M, Itzhar-Baïkian N, Dreyfus M, d'Oiron R, Borel-Derlon A, Susen S, Bezieau S, Denis CV, Goudemand J; French Reference Center for von Willebrand disease.

Medicine (Baltimore). 2016 Mar;95(11):e3038. doi: 10.1097/MD.0000000000003038.


Von Willebrand Factor--A New Target for TTP Treatment?

Veyradier A.

N Engl J Med. 2016 Feb 11;374(6):583-5. doi: 10.1056/NEJMe1515876. No abstract available.


A novel ELISA-based diagnosis of acquired von Willebrand disease with increased VWF proteolysis.

Rauch A, Caron C, Vincent F, Jeanpierre E, Ternisien C, Boisseau P, Zawadzki C, Fressinaud E, Borel-Derlon A, Hermoire S, Paris C, Lavenu-Bombled C, Veyradier A, Ung A, Vincentelli A, van Belle E, Lenting PJ, Goudemand J, Susen S.

Thromb Haemost. 2016 May 2;115(5):950-9. doi: 10.1160/TH15-08-0638. Epub 2016 Jan 21.


[Telemedicine in thrombotic microangiopathies: A way forward in rare diseases requiring emergency care].

Coppo P, Corre E, Rondeau E, Benhamou Y, Bachet A, Stépanian A, Veyradier A; Centre de référence des microangiopathies thrombotiques.

Rev Med Interne. 2016 Aug;37(8):514-20. doi: 10.1016/j.revmed.2015.10.354. Epub 2015 Dec 8. French.


Twice-daily therapeutical plasma exchange-based salvage therapy in severe autoimmune thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.

Soucemarianadin M, Benhamou Y, Delmas Y, Pichereau C, Maury E, Pène F, Halimi JM, Presne C, Thouret JM, Veyradier A, Coppo P.

Eur J Haematol. 2016 Aug;97(2):183-91. doi: 10.1111/ejh.12706. Epub 2016 Jan 6.


ADAMTS-13 and von Willebrand factor predict venous thromboembolism in patients with cancer.

Pépin M, Kleinjan A, Hajage D, Büller HR, Di Nisio M, Kamphuisen PW, Salomon L, Veyradier A, Stepanian A, Mahé I.

J Thromb Haemost. 2016 Feb;14(2):306-15. doi: 10.1111/jth.13205. Epub 2016 Jan 25.


[Thrombotic thrombocytopenic purpura in a newborn].

Ghariani I, Jmili-Braham N, Azzebi O, Kortas M, Veyradier A, Bakir L.

Arch Pediatr. 2016 Jan;23(1):78-81. doi: 10.1016/j.arcped.2015.09.032. Epub 2015 Nov 6. French.


Risk Factors for Autoimmune Diseases Development After Thrombotic Thrombocytopenic Purpura.

Roriz M, Landais M, Desprez J, Barbet C, Azoulay E, Galicier L, Wynckel A, Baudel JL, Provôt F, Pène F, Mira JP, Presne C, Poullin P, Delmas Y, Kanouni T, Seguin A, Mousson C, Servais A, Bordessoule D, Perez P, Chauveau D, Veyradier A, Halimi JM, Hamidou M, Coppo P; French Thrombotic Microangiopathies Reference Center.

Medicine (Baltimore). 2015 Oct;94(42):e1598. doi: 10.1097/MD.0000000000001598.


Coagulation Disorders and Bleedings in Critically Ill Patients With Hemophagocytic Lymphohistiocytosis.

Valade S, Azoulay E, Galicier L, Boutboul D, Zafrani L, Stepanian A, Canet E, Lemiale V, Venot M, Veyradier A, Mariotte E.

Medicine (Baltimore). 2015 Oct;94(40):e1692. doi: 10.1097/MD.0000000000001692.


Thrombotic thrombocytopenic purpura: from diagnosis to therapy.

Mariotte E, Veyradier A.

Curr Opin Crit Care. 2015 Dec;21(6):593-601. doi: 10.1097/MCC.0000000000000255. Review.


[Mild hemophilia A fortuitously discovered during Henoch-Schönlein purpura].

Joly B, d'Oiron R, Desconclois C, Bendelac L, Rafowicz A, Meyzer C, Labrune P, Veyradier A.

Arch Pediatr. 2015 Nov;22(11):1167-70. doi: 10.1016/j.arcped.2015.07.014. Epub 2015 Sep 26. French.


Rituximab in autoimmune thrombotic thrombocytopenic purpura: A success story.

Froissart A, Veyradier A, Hié M, Benhamou Y, Coppo P; French Reference Center for Thrombotic Microangiopathies.

Eur J Intern Med. 2015 Nov;26(9):659-65. doi: 10.1016/j.ejim.2015.07.021. Epub 2015 Aug 17. Review.


Incidence of obstetrical thrombotic thrombocytopenic purpura in a retrospective study within thrombocytopenic pregnant women. A difficult diagnosis and a treatable disease.

Delmas Y, Helou S, Chabanier P, Ryman A, Pelluard F, Carles D, Boisseau P, Veyradier A, Horovitz J, Coppo P, Combe C.

BMC Pregnancy Childbirth. 2015 Jun 17;15:137. doi: 10.1186/s12884-015-0557-5.


Are platelet transfusions harmful in acquired thrombotic thrombocytopenic purpura at the acute phase? Experience of the French thrombotic microangiopathies reference center.

Benhamou Y, Baudel JL, Wynckel A, Galicier L, Azoulay E, Provôt F, Pène F, Mira JP, Presne C, Poullin P, Halimi JM, Rivière E, Kanouni T, Seguin A, Mousson C, Servais A, Bordessoule D, Perez P, Hamidou M, Chauveau D, Veyradier A, Coppo P.

Am J Hematol. 2015 Jun;90(6):E127-9. doi: 10.1002/ajh.23997. No abstract available.


Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study From the SFGM-TC.

de Fontbrune FS, Galambrun C, Sirvent A, Huynh A, Faguer S, Nguyen S, Bay JO, Neven B, Moussi J, Simon L, Xhaard A, Resche-Riggon M, O'Meara A, Fremeaux-Bacchi V, Veyradier A, Socié G, Coppo P, de Latour RP.

Transplantation. 2015 Sep;99(9):1953-9. doi: 10.1097/TP.0000000000000601.


Secondary thrombotic microangiopathy in two patients with Philadelphia-positive hematological malignancies treated with imatinib mesylate.

Ojeda-Uribe M, Merieau S, Guillon M, Aujoulat O, Hinschberger O, Eisenmann JC, Kenizou D, Debliquis A, Veyradier A, Chantrel F.

J Oncol Pharm Pract. 2016 Apr;22(2):361-70. doi: 10.1177/1078155214568580. Epub 2015 Jan 14.


[The revolution of monoclonal antibodies in the treatment of thrombotic microangiopathy].

Sauvètre G, Grange S, Froissart A, Veyradier A, Coppo P, Benhamou Y.

Rev Med Interne. 2015 May;36(5):328-38. doi: 10.1016/j.revmed.2014.10.364. Epub 2014 Oct 31. Review. French.


Acute renal failure is prevalent in patients with thrombotic thrombocytopenic purpura associated with low plasma ADAMTS13 activity.

Zafrani L, Mariotte E, Darmon M, Canet E, Merceron S, Boutboul D, Veyradier A, Galicier L, Azoulay E.

J Thromb Haemost. 2015 Mar;13(3):380-9. doi: 10.1111/jth.12826. Epub 2015 Jan 29.


Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center.

Benhamou Y, Boelle PY, Baudin B, Ederhy S, Gras J, Galicier L, Azoulay E, Provôt F, Maury E, Pène F, Mira JP, Wynckel A, Presne C, Poullin P, Halimi JM, Delmas Y, Kanouni T, Seguin A, Mousson C, Servais A, Bordessoule D, Perez P, Hamidou M, Cohen A, Veyradier A, Coppo P; Reference Center for Thrombotic Microangiopathies.

J Thromb Haemost. 2015 Feb;13(2):293-302. doi: 10.1111/jth.12790. Epub 2014 Dec 18.


Metastatic cancer-related thrombotic microangiopathies: a cohort study.

Ducos G, Mariotte E, Galicier L, Canet E, Boutboul D, Lemiale V, Schlemmer B, Veyradier A, Azoulay E, Zafrani L.

Future Oncol. 2014 Aug;10(10):1727-34. doi: 10.2217/fon.14.113.


Evaluation of a chromogenic commercial assay using VWF-73 peptide for ADAMTS13 activity measurement.

Joly B, Stepanian A, Hajage D, Thouzeau S, Capdenat S, Coppo P, Veyradier A.

Thromb Res. 2014 Nov;134(5):1074-80. doi: 10.1016/j.thromres.2014.09.006. Epub 2014 Sep 16.


Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura.

Hie M, Gay J, Galicier L, Provôt F, Presne C, Poullin P, Bonmarchand G, Wynckel A, Benhamou Y, Vanhille P, Servais A, Bordessoule D, Coindre JP, Hamidou M, Vernant JP, Veyradier A, Coppo P; French Thrombotic Microangiopathies Reference Centre.

Blood. 2014 Jul 10;124(2):204-10. doi: 10.1182/blood-2014-01-550244. Epub 2014 May 28.


The prognostic value of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13) deficiency in septic shock patients involves interleukin-6 and is not dependent on disseminated intravascular coagulation.

Peigne V, Azoulay E, Coquet I, Mariotte E, Darmon M, Legendre P, Adoui N, Marfaing-Koka A, Wolf M, Schlemmer B, Veyradier A.

Crit Care. 2013 Nov 18;17(6):R273. doi: 10.1186/cc13115.


Evaluation of a commercial assay for ADAMTS13 activity measurement.

Thouzeau S, Capdenat S, Stépanian A, Coppo P, Veyradier A.

Thromb Haemost. 2013 Oct;110(4):852-3. doi: 10.1160/TH13-05-0393. Epub 2013 Jul 11. No abstract available.


Supplemental Content

Loading ...
Support Center